DL 2

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Retrieved on: 
Lundi, décembre 11, 2023
CRS, Patient, Cytokine, DL 2, Survival, Immune system, Hematopoietic stem cell transplantation, PIN, Plasma, Medical director, DL, Leukemia, Mortality, Principal investigator, MD, Graft-versus-host disease, Society, Haematopoietic system, Clinical trial, Infrared spectroscopy correlation table, Blood, Event, Bone marrow, ASH, Death, Observation, IL-6, Cytogenetics, Webcast, Gamma ray, HSCT, Acute myeloid leukemia, Safety, University, AML, NK, Pharmaceutical industry

Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Please use this link to participate in the live call; a listen-only version of the webcast is available here .
  • “Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need.
  • In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics.

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring

Retrieved on: 
Lundi, septembre 18, 2023
Perk, NRAS, Workforce, FGFR, DNA, Pancreatic cancer, DUSP6, PRS, Class II, Class, DCR, Clinical trial, DC, DL 2, Trae tha Truth, First grade, MEK inhibitor, BRAF, Research, Itch, MEK, RNA, Lung cancer, Completeness, Binimetinib, Rash, ORR, Vomiting, Investment, Patient, SAN, Melanoma, ERK, Weakness, Nausea, ALT, Neoplasm, CDK4, FDA, FGFR2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, SD, KNTE, Food, PR, Safety, Fatigue, RAF, Pharmaceutical industry, Cryptocurrency, Medical imaging, Vaccine

(Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.

Key Points: 
  • (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.
  • Additionally, Kinnate will pause development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248, as part of the reprioritization plan.
  • We believe that reprioritizing our programs is the most effective approach to unlock the full promise of our innovative therapies.”
    Farzan added, “The reprioritization plan unfortunately impacts our workforce.
  • Kinnate will implement a corporate restructuring by reducing the Company’s workforce by approximately 70%.

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

Retrieved on: 
Mercredi, mai 31, 2023
Interim, American Society of Clinical Oncology, Therapy, CRS, DL, DCR, DLT, DL 2, Oncology, Harvard Medical School, Presentation Public School, ASCO, TAC, MD, Patient, GEJ, Annual general meeting, Toxic epidermal necrolysis, ICU, ORR, News, Safety, Dana–Farber Cancer Institute, Pharmaceutical industry, Medicine

"We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.

Key Points: 
  • "We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with HER2-positive gastric and esophageal cancers."
  • Interim results from the Phase I TACTIC-02 study suggest a highly favorable safety profile for TAC-01 HER2 treatment with the potential of being an outpatient procedure.
  • A copy of the presentations will be available after the closure of the meeting, under the Presentations & Publications tab of the News & Resources section of the Company's website .

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

Retrieved on: 
Lundi, avril 17, 2023
Well, Class II, RECIST, DL 2, A2, MEK, Doctor of Philosophy, Plasma, MD, Patient, Carcinoma, KNTE, PRS, MBBS, Half-life, Response evaluation criteria in solid tumors, FACP, University of Virginia Cancer Center, Lung cancer, Binimetinib, Combination therapy, Neoplasm, Grade, Abstract, Skin, PR, Safety, RAF, NRAS, DNA, Index, AACR, Alanine transaminase, Papillary thyroid cancer, American Association for Cancer Research, BRAF, NSCLC, IC50, Colorectal cancer, SAN, MTD, ORR, Probability, Grade 3, Trae tha Truth, Part, Physician, Melanoma, Annual general meeting, Toxic leukoencephalopathy, SD, Pharmaceutical industry, Vaccine, Phosphorus, Generic drug, Medical imaging, Nursing, Cmax

“The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.

Key Points: 
  • “The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.
  • Treated patients included those with solid tumors driven by BRAF Class I (41.7%), Class II (13.3%) and Class III (30%) alterations or melanoma with NRAS mutations (15%).
  • Dose limiting toxicities observed at the highest dose level (400 mg bid) were Grade 3 acneiform rash (n=1) and Grade 3 macular rash (n=1).
  • Kinnate will prioritize development of the exarafenib combination in patients with NRAS mutant melanoma.

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR

Retrieved on: 
Lundi, avril 25, 2022
Patient, Drug development, Body surface area, Transplant, Leukapheresis, Investor relations, COVID-19, Risk, Research, NHL, DL 2, Refractory, ALL, Cell, NKT, NCCN, ClinicalTrials.gov, CAR, SEC, History, Safety, Relapse, NCI, Cancer, Pharmaceutical industry, KUUR

Response to therapy was assessed at 4 weeks per Lugano Criteria (for NHL) or NCCN guidelines (for ALL).

Key Points: 
  • Response to therapy was assessed at 4 weeks per Lugano Criteria (for NHL) or NCCN guidelines (for ALL).
  • The abstract Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies presented at the 2022 Transplantation & Cellular Tandem Meetings of ASTCT and CIBMTR can be viewed here .
  • Athenexs employees worldwide are dedicated to improving the lives of cancer patients by creating more active, accessible and tolerable treatments.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting

Retrieved on: 
Lundi, décembre 13, 2021
PR, CRi, KOL, Body surface area, Company, NHL, History, Cell, CR, Baylor College of Medicine, COVID-19, Cancer, NASDAQ, Risk, SEC, CD19, NKT, NCI, Patient, Safety, MD Anderson Cancer Center, Drug development, DL 2, Lymphoma, DL, Investor relations, NCCN, Leukemia, GLOBE, ClinicalTrials.gov, CAR, ALL, Leukapheresis, Pharmaceutical industry, KUUR

BUFFALO, N.Y., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it will host a virtual Key Opinion Leader (KOL) event today at 9:00am ET to discuss its NKT cell therapy programs.

Key Points: 
  • At the ASH Annual Meeting yesterday, the Company provided updated results from the study, which included a conversion of one patient (NHL-4) treated with dose level (DL) 2, from a PR to a CR.
  • Safety profile of treatment with the allogeneic CAR-NKT cells remains favorable and further enrollment is ongoing.
  • The webinar will feature presentations by KOLs Leonid Metelitsa, M.D., and Carlos Ramos, M.D., both from Baylor College of Medicine, and Sattva Neelapu, M.D., from MD Anderson Cancer Center.
  • Dr. Ramos will discuss the interim data from the ongoing ANCHOR study evaluating KUR-502 in relapsed or refractory lymphoma and leukemia.

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition

Retrieved on: 
Jeudi, novembre 4, 2021
Safety, Exposition, Neoplasm, Baylor University, History, CAR, ASH, Nausea, Cell, Baylor College of Medicine, Body surface area, Communication, Center for Cell and Gene Therapy, NCI, COVID-19, Gene, GLOBE, Toxic epidermal necrolysis, Houston Methodist Hospital, Real-time, Interim analysis, Leukemia, NKT A/S, Flow cytometry, II, ALL, Relapse, HLA, Acute lymphoblastic leukemia, DL 2, CRi, CD19, Drug development, SEC, Risk, Center, Hospital, Corporate development, Population, Patient, Society, NHL, Cancer, NCCN, Leukapheresis, NASDAQ, NKT, Adult, Principal investigator, Investor relations, ClinicalTrials.gov, Pharmaceutical industry

BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today data from the ANCHOR Phase 1 study of KUR-502 to be highlighted in a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 11th to December 14th, 2021. The data demonstrates that allogeneic CD19 CAR-NKT cells are well-tolerated and can mediate objective responses in B-cell relapsed/refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) patients even at the low doses tested.

Key Points: 
  • Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients treated with low doses of KUR-502.
  • The data demonstrates that allogeneic CD19 CAR-NKT cells are well-tolerated and can mediate objective responses in B-cell relapsed/refractory non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) patients even at the low doses tested.
  • We are encouraged that we have been able to demonstrate homing of allogeneic CAR-NKT cells to tumor, which is a differentiating feature of this platform.
  • There were no early adverse events attributable to the cellular product except grade 1 cytokine release syndrome in one patient.